Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors
The Annual General Meeting 2024 of Scandion Oncology A/S (the "Company") was held on 6 May 2024 at 2:00 p.m.
All proposals were adopted in accordance with the notice.
After the general meeting, the board of directors constituted itself with Martin Møller as chairman and Alejandra Mørk as deputy chairman.
The full minutes of the annual general meeting are attached to this announcement.
The agenda of the annual general meeting was as follows:
| Election of chairman of the meeting |
| Report from the board of directors on the Company's business in the past year |
| Presentation of the audited annual report for approval |
| Proposal of notice of discharge to the board of directors and the executive board |
| Decision on appropriation of profit or loss as recorded in the approved annual report |
| Proposal to authorize the board of directors to issue shares with pre-emptive rights for the Company's existing shareholders |
| Proposal to authorize the board of directors to issue warrants (TO 2) and any related capital increase(s) |
| Proposal to authorize the board of directors to issue warrants (TO 3) and any related capital increase(s) |
| Proposal to authorize the board of directors to issue shares without pre-emptive rights for the Company's existing shareholders |
| Proposal to amend article 9.1 of the articles of association regarding the number of members of the board of directors and some linguistic clean-up in article 6.3 (English version) |
| Proposal of approval of the board of directors' fee for 2024 |
| Election of members of the board of directors |
| Election of auditor |
| Any other business |
For further information, please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com
The information was provided by the contact person above for publication on 6 May 2024 at 16.30 CET.
Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.
Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.
Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.
